Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cyclophosphamide
/ pharmacology
Doxorubicin
/ pharmacology
Female
Humans
Lymphoma, Mantle-Cell
/ diagnostic imaging
Male
Middle Aged
Positron-Emission Tomography
/ methods
Prednisone
/ pharmacology
Prognosis
Progression-Free Survival
Rituximab
/ pharmacology
Vincristine
/ pharmacology
R-CHOP
interim 18F-FDG PET
mantle cell lymphoma
prognosis
treatment response
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
14
05
2019
accepted:
23
09
2019
pubmed:
17
11
2019
medline:
18
11
2020
entrez:
17
11
2019
Statut:
ppublish
Résumé
Although
Identifiants
pubmed: 31733125
doi: 10.1111/bjh.16257
pmc: PMC7155042
doi:
Substances chimiques
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
860-871Subventions
Organisme : Korea Healthcare Technology R&D Project
Pays : International
Organisme : Ministry for Health, Welfare, and Family Affairs, Republic of Korea
Pays : International
Organisme : National Research Foundation of Korea
Pays : International
Organisme : Ministry of Education, Science, and Technology
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
J Clin Oncol. 2016 Apr 10;34(11):1256-69
pubmed: 26755518
Expert Opin Pharmacother. 2015;16(16):2497-507
pubmed: 26360791
J Clin Oncol. 2005 Oct 1;23(28):7013-23
pubmed: 16145068
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64
pubmed: 22198543
Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1312-20
pubmed: 23649463
Bone Marrow Transplant. 2010 Apr;45(4):801-2
pubmed: 19767780
J Clin Oncol. 2013 Apr 10;31(11):1442-9
pubmed: 23401442
J Nucl Med. 2017 Jan;58(1):62-68
pubmed: 27469362
Am J Hematol. 2011 Oct;86(10):841-5
pubmed: 21922524
Leukemia. 2014 Nov;28(11):2117-30
pubmed: 24854989
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Nucl Med. 2017 Oct;58(10):1539-1544
pubmed: 28798034
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Expert Rev Hematol. 2015 Aug;8(4):493-504
pubmed: 26091558
Leuk Lymphoma. 2012 Oct;53(10):1876-81
pubmed: 22432519
Blood. 2010 Aug 19;116(7):1092-104
pubmed: 20435884
Clin Cancer Res. 2014 Oct 15;20(20):5194-206
pubmed: 25320369
Br J Haematol. 2012 Aug;158(3):355-62
pubmed: 22640180
Blood. 2014 Aug 21;124(8):1288-95
pubmed: 24859361
Bone Marrow Transplant. 2019 Feb;54(2):330-333
pubmed: 30082849
Leuk Lymphoma. 2014 Nov;55(11):2484-9
pubmed: 24432895
J Nucl Med. 2013 May;54(5):683-90
pubmed: 23516309
Leuk Lymphoma. 2008 Sep;49(9):1693-701
pubmed: 18798104
Cancer. 2012 Jul 15;118(14):3565-70
pubmed: 22180256
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110
pubmed: 28411336
Nucl Med Commun. 2009 Oct;30(10):770-8
pubmed: 19657307
J Clin Oncol. 2007 Feb 10;25(5):571-8
pubmed: 17242397